Selective Akt3 Inhibitor Modulates Treg Immune Function

The patent applies segmentation by designing inhibitors that target specific Akt3 structural features distinct from Akt1 and Akt2. The compound structure is segmented to interact with unique regions of Akt3, such as the hydrophobic groove and specific amino acid residues, thereby achieving isoform-selective inhibition without affecting other Akt isoforms that have redundant functions in other cellular processes.

The patent employs local quality by modifying specific regions of the inhibitor molecule to enhance binding affinity for Akt3-specific pockets while maintaining selectivity. The compound contains functional groups positioned to interact with unique local features of Akt3's active site, including hydrogen bonding with specific residues and hydrophobic interactions with the P-loop region, ensuring selective inhibition.

The patent applies the taking out principle by selectively extracting or inhibiting Akt3 signaling specifically within Tregs, rather than depleting Tregs entirely. The compound penetrates Tregs and selectively blocks Akt3 kinase activity, thereby removing the suppressive function mediated by Akt3 while preserving other Treg functions that maintain immune homeostasis and prevent autoimmunity.

Instead of depleting Tregs to reduce autoimmunity (which harms anti-tumor immunity), the patent inverts the approach by preserving Tregs but selectively inhibiting their suppressive function through Akt3 blockade. This allows Tregs to maintain homeostatic functions while their immunosuppressive activity is reversed or reduced, enabling both autoimmunity control and anti-tumor immunity enhancement.